Skip to main content
Premium Trial:

Request an Annual Quote

Indian Firm Ocimum Raises $8M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian firm Ocimum Biosolutions today announced it has closed on an $8 million round, which it will use to enhance its Research as a Service platform.

The company, based in Hyderabad, said that investors came from multiple sources, including its founders and existing shareholders. It provides a wide array of services including GLP-compliant microarray services, genomic reference databases, life science laboratory management solutions, and research consumables.

Its RaaS platform allows for the complete outsourcing of genomics from storage of biological samples to DNA- and RNA-based services to biomarker validation. The company also said that part of the financing will go toward completion of a 360,000-square-foot facility, which will house Ocimum's GLP-compliant, genomic, and diagnostics laboratories.

Ocimum added that it intends to expand its offerings to cover the entire drug discovery market and will add new offerings to support clinical trial support services, biomarker discovery, and biobanking.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.